Phase-1B Biopharma (1,910 companies)
128 Companies
Access all companiesSpotfolio tracks over one million companies in technology industries.
There are 128 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Therapeutics, Biopharmaceutical, Patients, Clinical-Development, Therapies, Clinical-Trials, Drug, Phase-1B .
Start-ups (17)
Early-stage companies (38)
Established companies (67)
The majority of these companies is located in the following countries.
United States (85)
Canada (6)
China (6)
France (5)
Example Companies
Find companies in your areaCureDM CureDM,Inc.

Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Download CureDM Announces Results of Phase 1b Study in Type 2 Diabetes Patients March 20, 2016 /news/CureDM-Completes-Phase-1b-Study-in-Type-2-Diabetes-Patients ...
Download CureDM Initiates Phase 1b Safety Study in type 2 Diabetes Patients September 10, 2013 /news/CureDM-Initiates-Phase-1b-in-Type-2-Diabetes-Patients
AviaraMD AviaraMD, LLC

Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Download CureDM Announces Results of Phase 1b Study in Type 2 Diabetes Patients March 20, 2016 /news/CureDM-Completes-Phase-1b-Study-in-Type-2-Diabetes-Patients ...
Download CureDM Initiates Phase 1b Safety Study in type 2 Diabetes Patients September 10, 2013 /news/CureDM-Initiates-Phase-1b-in-Type-2-Diabetes-Patients
OncXerna Therapeutics OncXerna Therapeutics, Inc.

Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer. Fu ...
Pre-treated Platinum Resistant Ovarian Cancer Overall response rate in the Phase 1b trial was 21% (95% CI: 6-45%) • Demcizumab is an IgG2 monoclonal antibody ...
was more severe at higher doses (4 - Grade 2, 1 - Grade 3) 6/9/2020 13 Phase 1B Study: Navicixizumab Plus Paclitaxel in Patients with Ovarian, Peritoneal ...
Immunogenicity Trial location • 7 US sites 14 Data-cut January 15, 2020 Phase 1B Study of Navicixizumab Plus Paclitaxel in PROC Patients: Demographics 3 ...
Protocol deviation. ** 1 patient received Abraxane® Data-cut January 15, 2020 Phase 1B Study of Navicixizumab Plus Paclitaxel in PROC Patients: RECIST Response ...
response rate was 16/44 (36%). ** CR+PR+SD Data-cut January 15, 2020 Phase 1B Study of Navicixizumab Plus Paclitaxel in PROC Patients: Best % Change
LianBio

Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
and immune checkpoint receptors to regulate their signaling. Phase 1b BBP-398 Phase 1b Disease: Signaling pathways that regulate cell proliferation ...
given the large population. Development plans: Lianbio is undertaking Phase 1b combo escalation studies in China for BBP-398 in combination with various
Kato Pharmaceuticals Kato Pharmaceuticals, Inc.

Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Product Overview - Resolv ER™ - Mechanism of Action - Clinical Trials - Phase 1B - Phase 2 - Image Gallery - About Us - Leadership - Scientific Advisors ...
- Phase 1B - Phase 2 - Image Gallery - About Us - Leadership - Scientific Advisors - Our Partners Phase 1B Kato Pharmaceuticals > Phase 1B For
Product Overview - Resolv ER™ - Mechanism of Action - Clinical Trials - Phase 1B - Phase 2 - Image Gallery - About Us - Leadership - Scientific Advisors ...
Product Overview - Resolv ER™ - Mechanism of Action - Clinical Trials - Phase 1B - Phase 2 - Image Gallery - About Us - Leadership - Scientific Advisors
Topics
Search by any topicOnly spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.
Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.
- Advancing-Novel
- Argotpartners
- CTLA4
- Cancer-Ther
- Deducting-Underwriting-Discounts
- Disease-Therapeutics
- Dose-Escalation-Trial
- Evaluable-Patients
- Expansion-Cohort
- Jefferies-Virtual-Healthcare
- Limiting-Toxicity
- Median-Duration
- Median-PFS
- Mg-QD
- Mol-Cancer
- Mol-Cancer-Ther
- Phase-2B-Study
- Solebury-Trout
- Tumor-Regression
The following topics addressed by the majority of companies help you discover major players in the field.
- 1B-Clinical
- 1B-Clinical-Trial
- 1B-Study
- 1B-Trial
- 2A-Clinical-Trial
- 2A-Study
- Advanced-Solid
- Advanced-Solid-Tumors
- Dose-Escalation-Study
- Dose-Expansion
- Dose-Limiting
- Escalation-Study
- Investigational-Medicines
- Maximum-Tolerated
- Mg-BID
- Objective-Response
- Offering-Expenses
- Oncology-Programs
- Partial-Response
- Patient-Dosed
- Phase-1A
- Phase-1B
- Phase-1B-Clinical
- Phase-1B-Study
- Phase-Ib
- Product-Candidates
- RECIST
- Registrational
- Stable-Disease
- TEAE
- Treatment-Emergent
- Underwriting-Discounts
All companies in this field address the following more general topics.
- Biopharmaceutical
- Biopharmaceutical-Company
- Biotechnology
- Board
- Cell
- Chief
- Clinical
- Clinical-Development
- Clinical-Stage
- Clinical-Trials
- Development
- Director
- Disease
- Dose
- Dr
- Drug
- Efficacy
- FDA
- Forward-Looking
- Forward-Looking-Statements
- Medical
- Medicine
- Novel
- Officer
- Oncology
- Patients
- Pharmaceutical
- Phase
- Phase-2
- Pipeline
- Preclinical
- President
- Research
- Scientific
- Study
- Therapeutics
- Therapies
- Treatment
- Trials
- University
Use Cases
Register nowTechnology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.
Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.